Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy APLS?
Source: seekingalpha
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments initiated a new stake in Apellis Pharmaceuticals during Q4 2026 by acquiring 7,666,764 shares valued at $192.59 million, reflecting a strategic confidence in the company.
- Asset Allocation Insight: As of December 31, 2025, Apellis accounted for 1.93% of RTW's 13F reportable AUM, indicating its growing significance within the investment portfolio.
- Market Performance Review: Despite a 29% decline in Apellis's stock price over the past year, currently priced at $17.21, the company generated approximately $689 million in product revenue last year, demonstrating strong demand in the rare disease market.
- Strategic Investment Shift: RTW's portfolio is heavily weighted towards high-growth biotech firms, and the addition of Apellis is viewed as a calculated pivot towards more stable revenue streams, potentially offering investors a better risk-reward profile.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments established a new position in Apellis Pharmaceuticals by acquiring 7,666,764 shares in Q4 2026, valued at $192.59 million, reflecting confidence in the company despite its 1.93% portfolio allocation.
- Revenue Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy contributing about $587 million, indicating strong demand and expanding market share in the rare disease sector.
- Portfolio Diversification: RTW's portfolio is heavily weighted towards high-growth biotech firms like Madrigal and Insmed, while the sub-2% stake in Apellis suggests a strategic pivot towards more stable revenue streams without sacrificing upside potential.
- Market Competitive Advantage: Apellis focuses on innovative therapies for complement-driven diseases, leveraging a robust pipeline and strategic collaborations to enhance its competitive position in the rare disease and specialty therapeutics market, despite its stock performance falling short of expectations.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments initiated a new stake in Apellis Pharmaceuticals during Q4 2026 by acquiring 7,666,764 shares valued at $192.59 million, reflecting a strategic confidence in the company.
- Asset Allocation Insight: As of December 31, 2025, Apellis accounted for 1.93% of RTW's 13F reportable AUM, indicating its growing significance within the investment portfolio.
- Market Performance Review: Despite a 29% decline in Apellis's stock price over the past year, currently priced at $17.21, the company generated approximately $689 million in product revenue last year, demonstrating strong demand in the rare disease market.
- Strategic Investment Shift: RTW's portfolio is heavily weighted towards high-growth biotech firms, and the addition of Apellis is viewed as a calculated pivot towards more stable revenue streams, potentially offering investors a better risk-reward profile.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments established a new position in Apellis Pharmaceuticals by acquiring 7,666,764 shares in Q4 2026, valued at $192.59 million, reflecting confidence in the company despite its 1.93% portfolio allocation.
- Revenue Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy contributing about $587 million, indicating strong demand and expanding market share in the rare disease sector.
- Portfolio Diversification: RTW's portfolio is heavily weighted towards high-growth biotech firms like Madrigal and Insmed, while the sub-2% stake in Apellis suggests a strategic pivot towards more stable revenue streams without sacrificing upside potential.
- Market Competitive Advantage: Apellis focuses on innovative therapies for complement-driven diseases, leveraging a robust pipeline and strategic collaborations to enhance its competitive position in the rare disease and specialty therapeutics market, despite its stock performance falling short of expectations.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
